CN103341167B - Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution - Google Patents
Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution Download PDFInfo
- Publication number
- CN103341167B CN103341167B CN201310282056.6A CN201310282056A CN103341167B CN 103341167 B CN103341167 B CN 103341167B CN 201310282056 A CN201310282056 A CN 201310282056A CN 103341167 B CN103341167 B CN 103341167B
- Authority
- CN
- China
- Prior art keywords
- acetic acid
- acetum
- add
- acid solution
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229960000583 acetic acid Drugs 0.000 claims abstract description 26
- 229940124307 fluoroquinolone Drugs 0.000 claims abstract description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 4
- 239000001632 sodium acetate Substances 0.000 claims abstract description 4
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 9
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 229950001733 difloxacin Drugs 0.000 claims description 3
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 229950007734 sarafloxacin Drugs 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 24
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 241000233866 Fungi Species 0.000 abstract description 5
- 235000019445 benzyl alcohol Nutrition 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 241000700605 Viruses Species 0.000 abstract description 4
- 239000000243 solution Substances 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 3
- 210000004666 bacterial spore Anatomy 0.000 abstract description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 2
- 238000006114 decarboxylation reaction Methods 0.000 abstract description 2
- 229960001484 edetic acid Drugs 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 abstract 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 9
- 229960001699 ofloxacin Drugs 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- 239000003221 ear drop Substances 0.000 description 3
- 229940047652 ear drops Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000004215 spore Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960000740 enrofloxacin Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960004236 pefloxacin Drugs 0.000 description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001425718 Vagrans egista Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- -1 aromatic alcohols Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound acetic acid solution for veterinary use and a preparation process of the compound acetic acid solution. Each 1L of the compound acetic acid solution for the veterinary use consists of 8-30g of glacial acetic acid, 1-6g of sodium acetate, 1-6g of PVP-K30, 1-5g of fluoroquinolone medicines, 0.5-1.5g of sodium hydrogen sulfite, 10-35g of benzyl alcohol, 0.8-1.5g of EDTA (Ethylene Diamine Tetraacetic Acid)-2Na, 0.8-2g of Tween-80, 10-200g of propylene glycol, 50-300g of glycerol and injection water for the balance, wherein the benzyl alcohol has antibacterial, pain-relieving and anti-itching functions; the PVP (Poly Vinyl Pyrrolidone)-K30 has a film forming property, so as to inhibit odor from spreading and relieve water volatilization; fluoroquinolone medicines, belonging to a broad-spectrum bactericidal medicine, can enhance speed and effect of the acetic acid to kill fungi, viruses, bacteria and bacterial spores; the acetic acid, as carboxylic acid, can prevent the fluoroquinolone medicines from decarboxylation, thus improving the stability of fluoroquinolone medicines.
Description
Technical field
The present invention relates to the technical field of acetum, particularly relate to a kind of animal compound acetum and preparation technology thereof.
Background technology
Acetic acid, has another name called acetic acid, and it is that one is extensively present in nature organic compound, is the important containing oxygen derivative of hydrocarbon, is typical fatty acid; It is the main component of vinegar.In the family, acetic acid dilute solution is often used as scale remover; Food industry aspect, acetic acid is a kind of acidity regulator of regulation; In medical and health, acetic acid is a kind of Cidex-7.Acetum all has stronger killing action to antibacterial, fungus, spore and virus.In general, acetum is the strongest to the killing action of bacterial propagule, is followed successively by fungus, virus, tubercule bacillus and bacterial spore.The acetic acid of 1% kills the strongest pathogen of resistance as fungus, enterovirus and spore etc., only take 10 minutes, but when spore is protected by Organic substance, action time then extends to 30 minutes.But as the material that a kind of acidity is stronger, when acetic acid is directly applied, there is zest strong, to untoward reaction such as skin, mucosa are corrosive during high concentration.
When current beasts are due to bacterial infective diseases, the product mainly ofloxacin ear drops used, its tool broad-spectrum antibacterial action, especially high to the antibacterial activity of aerobic gram negative bacilli, to the following antibacterial good antibacterial action of tool in vitro: most of antibacterial of enterobacteriaceae, comprises Enterobacter, escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, vibrio, the yersinias etc. such as bacillus citrate genus, cloaca, clostridium perfringen.Often also there is antibacterial activity to multi-drug resistant bacteria.To the Diplococcus gonorrhoeae of Penicillin-resistant, produce enzyme hemophilus influenza and Moraxella all has height antibacterial activity.To most of bacterial strain tool antibacterial actions of the Rhodopseudomonass such as Pseudomonas aeruginosa.This product to methicillin-sensitivity staphylococcus tool antibacterial activity, to streptococcus pneumoniae, Hemolytic streptococcus and the enterococcus faecalis only medium antibacterial activity of tool.To chlamydia trachomatis, mycoplasma, the good anti-microbial effect of legionella tool, also there is antibacterial activity to tubercule bacillus and anonymous mycobacteria.Poor to the antibacterial activity of anaerobe.Ofloxacin is antibacterial, by acting on the A subunit of DNA of bacteria helicase, suppressing the synthesis of DNA and copies and cause bacterial death.
As Chinese patent CN200910236327.8 discloses a kind of ofloxacin injection, adopt vinegar acid instead of HCl as cosolvent, and the polarity of adding propylene glycol adjusting agent is to improve the dissolubility of ofloxacin, thus solve the problem of the easy crystallization of ofloxacin injection liquid drugs injection.The injection quality stability that this invention provides is good, but acetic acid wherein could not give play to the bactericidal effect of its uniqueness.
Summary of the invention
In view of this, the invention provides a kind of animal compound acetum and preparation technology thereof, can solve zest problem when acetum uses, the bactericidal effect of acetic acid is remarkable.
For solving above technical problem, technical scheme of the present invention is, provides a kind of animal compound acetum, and the constituent of described animal compound acetum comprises benzyl alcohol, fluoroquinolones.
Preferably, described fluoroquinolones is mixture that in norfloxacin, difloxacin, ciprofloxacin, enrofloxacin, sarafloxacin, pefloxacin, ofloxacin, any one or any two are above.
Preferably, the composition of every 1L animal compound acetum comprises:
Preferably, the composition of every 1L animal compound acetum comprises:
The preparation technology of above-mentioned animal compound acetum, comprises the steps:
Various material amounts under calculating each prescription by configuration 100L gauge, and get the raw materials ready according to consumption; Get 40L water for injection in dosing cylinder, be heated to 80 DEG C, under stirring, add the EDTA-2Na of Formulation amount, sodium sulfite respectively successively, PVP-K30, make it to dissolve completely, then add tween 80; And then add fluoroquinolones, stir, and slowly add glacial acetic acid, stir and fluoroquinolones is dissolved completely; Be chilled to room temperature, add benzyl alcohol, propylene glycol, glycerol, and add water for injection to 95L, stir; Be 4.0 with sodium acetate adjust pH, be settled to 100L with water for injection, filter subpackage.
Compared with prior art, tool of the present invention has the following advantages:
One, the present invention adds a kind of benzyl alcohol of a large amount of aromatic alcohols, has pure and fresh fragrance, can cover the taste of acetic acid, and reduce the zest of acetic acid, PVP-K30 has film property, and acetic acid abnormal smells from the patient can be suppressed to spread; Fluoroquinolones combined effect is added in order to improve bactericidal action, fluoroquinolones is mixture that in norfloxacin, difloxacin, ciprofloxacin, enrofloxacin, sarafloxacin, pefloxacin, ofloxacin, any one or any two are above, various germ killing drugs are mutually promoted sterilization, promote speed and the effect of acetic acid killing fungus, virus and bacterial spore; Acetic acid, as carboxylic acid, can prevent fluoroquinolones decarboxylation, improves the stability of fluoroquinolones.
Two, the present invention applies fluoroquinolones, glacial acetic acid and benzyl alcohol are bactericide, but respective sterilization mechanism is different, each other without antagonism; On the contrary, the antibacterial all responsive for these three kinds of medicines, because attacking by three kinds of different modes simultaneously, the time that antibacterial is killed will shorten greatly, the degree that antibacterial is killed is more thorough, antibacterial is also difficult to produce drug resistance to three kinds of medicines simultaneously, thus avoids the situation producing drug resistance because of life-time service the present invention to occur.In the present invention, fluoroquinolones, glacial acetic acid and benzyl alcohol compatibility use, and expand the antimicrobial spectrum of product, thus have also been enlarged the scope of application of the present invention, make the control of the diseases such as " mixed infection " type tinea become simpler.The benzyl alcohol that the present invention applies has local anesthesia effect, can anaesthetize tinea, ear inflammation diseased region because of pathological changes or the pain produced because of diseased region irriate or pruritus, thus make the present invention have pain relieving, antipruritic function.
Detailed description of the invention
In order to make those skilled in the art understand technical scheme of the present invention better, below in conjunction with specific embodiment, the present invention is described in further detail.
Below in conjunction with embodiment, the specific embodiment of the present invention is further described.Following examples only for technical scheme of the present invention is clearly described, and can not limit the scope of the invention with this.
Embodiment one
The composition of every 1L animal compound acetum comprises:
Embodiment two
The composition of every 1L animal compound acetum comprises:
Embodiment three
The composition of every 1L animal compound acetum comprises:
Embodiment four
The composition of every 1L animal compound acetum comprises:
Embodiment five
The composition of every 1L animal compound acetum comprises:
Embodiment six
The composition of every 1L animal compound acetum comprises:
The preparation technology of the animal compound acetum of embodiment one to embodiment six is as follows:
Various material amounts under calculating each prescription by configuration 100L gauge, and get the raw materials ready according to consumption; Get 40L water for injection in dosing cylinder, be heated to 80 DEG C, under stirring, add the EDTA-2Na of Formulation amount, sodium sulfite respectively successively, PVP-K30, make it to dissolve completely, then add tween 80; And then add fluoroquinolones, stir, and slowly add glacial acetic acid, stir and fluoroquinolones is dissolved completely; Be chilled to room temperature, add benzyl alcohol, propylene glycol, glycerol, and add water for injection to 95L, stir; Be 4.0 with sodium acetate adjust pH, be settled to 100L with water for injection, filter subpackage.
Below with regard to the experiment Analysis such as various parameters, drug effect of the animal compound acetum of embodiment one to embodiment six:
Therapeutic evaluation: get product by each formula preparation respectively for clinical case, observe therapeutic effect, be chosen as " generally " with the curative effect of embodiment one products obtained therefrom, and as reference, the curative effect of other prescription products obtained therefroms is evaluated, the results are shown in Table 1;
Pain relieving/antipruritic effect evaluation: get product by each formula preparation respectively for clinical case, observe the reaction of medication ill domestic animal after 5 minutes, be chosen as "None" with the curative effect of embodiment one products obtained therefrom, and as with reference to evaluating the curative effect of other prescription products obtained therefroms, the results are shown in Table 1;
Moisture retention is evaluated: under room temperature, get respectively and drip in the exposed epidermis of animal by the product of each formula preparation, observe often drip medicine volatilize the time, the time of volatilizing is less than 20 minutes and is chosen as " poor ", the time that volatilizes was chosen as " good " between 20 minutes to 40 minutes, the time of volatilizing is greater than 40 minutes and is chosen as " excellent ", the results are shown in Table 1;
Frost resistance is evaluated: get respectively and after subzero 16 degree of freeze overnight, take out observation by the product of each formula preparation, after glaciation, thawing time is greater than 1 hour and is chosen as " poor ", after glaciation, thawing time is less than 1 hour and is chosen as " good ", and non-glaciation is chosen as " excellent ", the results are shown in Table 1;
Table 1 animal compound acetum prescription and process implementing evaluation of result
Listed 4 indexs of his-and-hers watches 1 are carried out comprehensive analysis and can be obtained: embodiment two to six is all more excellent compared with the prescription of embodiment one, wherein again with embodiment five prescription for optimum.
It is as follows that animal compound acetum investigates situation to the prevention effect of pet dog otitis media:
Material: animal compound acetum (preparing by example five); Ofloxacin ear drops (0.3%, market purchasing); Experimental dog (vagrant dog asylum otitis media in In The Suburbs of Chengdu suffers from dog 17, and body weight is about 10kg).
Method: trouble dog is divided into experimental group, positive controls and negative control group at random; Experimental group, with dog 6, adopts and drips ear mode administration animal compound acetum, each 2 of every bar dog every ear, every day 2 times; Positive controls and use dog 6, adopt and drip an ear mode administration ofloxacin ear drops, carry out ear and bathe 5 minutes, each 2 of every bar dog every ear, every day 2 times after administration; Negative control group with dog 5, not administration; Be used in conjunction 2 weeks, the results are shown in Table 2.
Table 2 animal compound acetum prevents and treats experimental result to pet dog otitis media
Clinical effect trial shows, experimental group therapeutic effect is obviously better than matched group, after sick dog uses animal compound acetum, namely the uneasy symptom caused because of pain/pruritus obviously alleviated after dripping medicinal liquid, repeatedly after medication, have cerumen to get rid of, the foreign odor caused because of otitis alleviates or disappears.
Below be only the preferred embodiment of the present invention, it should be pointed out that above-mentioned preferred implementation should not be considered as limitation of the present invention, protection scope of the present invention should be as the criterion with claim limited range.For those skilled in the art, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made and also should be considered as protection scope of the present invention.
Claims (2)
1. an animal compound acetum, is characterized in that, every 1L animal compound acetum is made up of following component:
Described fluoroquinolones is difloxacin and/or sarafloxacin.
2. the preparation technology of animal compound acetum as claimed in claim 1, is characterized in that, comprise the steps:
Various material amounts under calculating each prescription by configuration 100L gauge, and get the raw materials ready according to consumption; Get 40L water for injection in dosing cylinder, be heated to 80 DEG C, under stirring, add the EDTA-2Na of Formulation amount, sodium sulfite respectively successively, PVP-K30, make it to dissolve completely, then add tween 80; And then add fluoroquinolones, stir, and slowly add glacial acetic acid, stir and fluoroquinolones is dissolved completely; Be chilled to room temperature, add benzyl alcohol, propylene glycol, glycerol, and add water for injection to 95L, stir; Be 4.0 with sodium acetate adjust pH, be settled to 100L with water for injection, filter subpackage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310282056.6A CN103341167B (en) | 2013-07-05 | 2013-07-05 | Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310282056.6A CN103341167B (en) | 2013-07-05 | 2013-07-05 | Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103341167A CN103341167A (en) | 2013-10-09 |
| CN103341167B true CN103341167B (en) | 2015-03-18 |
Family
ID=49276026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310282056.6A Expired - Fee Related CN103341167B (en) | 2013-07-05 | 2013-07-05 | Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103341167B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434452A (en) * | 2015-11-26 | 2016-03-30 | 洛阳市兽药厂 | Preparation technology of compound gatifloxacin injection for dogs |
| CN110141550A (en) * | 2019-07-09 | 2019-08-20 | 武汉兴华智慧医药科技有限公司 | A kind of lavo-ofloxacin oral administration solution and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA92423C2 (en) * | 2009-07-24 | 2010-10-25 | Анатолій Альбертович Кузьмін | Antibacterial composition |
| CN102091087A (en) * | 2010-12-10 | 2011-06-15 | 上海恒丰强动物药业有限公司 | Acidic enrofloxacin injection and preparation method thereof |
-
2013
- 2013-07-05 CN CN201310282056.6A patent/CN103341167B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103341167A (en) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10016380B2 (en) | Antimicrobials and methods of use thereof | |
| CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
| WO2017101790A1 (en) | Pharmaceutical composition for treating cutaneous pruritus and use thereof | |
| CN107582459B (en) | A kind of preservative and preparation method thereof containing Fructus Forsythiae | |
| US20200171077A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
| TWI538682B (en) | The use of the extract toon | |
| CN101590287B (en) | Wound filling | |
| JP2022085809A (en) | Compound marbofloxacin spray and preparation method therefor | |
| CN109077945A (en) | Combined bacteriostat with lysozyme for cosmetics | |
| CN102525841A (en) | Marine organism bacterium-removal oral care liquid | |
| CN103341167B (en) | Compound acetic acid solution for veterinary use and preparation process of compound acetic acid solution | |
| JP2005200339A (en) | Antimicrobial agent | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| JP2004509636A (en) | Water-based disinfectant / disinfectant for food | |
| CN113995744A (en) | Composition and antibacterial application thereof | |
| CN104430575B (en) | For the thimerosal and preparation method sterilized in ward | |
| CN104523466A (en) | Chinese herbal medicinal skin mucosa disinfection wet wipe | |
| CN103340878B (en) | Compound ofloxacin solution for veterinary use and preparation process of compound ofloxacin solution | |
| CN104000767B (en) | A kind of Feminine care solution and preparation method thereof | |
| CN111328811B (en) | Low-concentration alcohol sterilization disinfectant and application thereof | |
| CN103202881A (en) | External agent composition for treating rash | |
| KR102051612B1 (en) | Composition for sterilization using synergistic antimicrobial effect of thiamine dilaurylsulfate and medium chain fatty acid | |
| CN101310702B (en) | Emulsion type gel preparation containing chlorhexidine and alcohol | |
| CN108904527A (en) | Composite skin sterilizing liquid composite and preparation method thereof | |
| WO2019239419A1 (en) | Methanoic acid composition and it's uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee after: Chengdu Qiankun animal pharmaceutical Limited by Share Ltd Address before: 611137, Wenjiang District, Sichuan City, Chengdu province science and Technology Industrial Development Zone on both sides of the road, Golden House Road 259 Patentee before: Chengdu Qiankun Animal Pharmaceutical Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150318 Termination date: 20190705 |